A Dual-Route Perspective of SARS-CoV-2 Infection: Lung- vs. Gut-specific Effects of ACE-2 Deficiency
Open Access
- 11 June 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 684610
Abstract
SARS-CoV-2, primarily considered a respiratory virus, is increasingly recognized as having gastrointestinal aspects based on its presence in the gastrointestinal (GI) tract and feces. SARS-CoV-2 uses as a receptor angiotensin-converting enzyme 2 (ACE-2), a critical member of the renin-angiotensin-aldosterone system (RAAS) involved in the regulation of blood pressure and fluid system. In addition to the systemic endocrine functions, RAAS components are also involved in intracrine and organ-specific local functions. The angiotensin-converting enzyme 2 (ACE-2) is a key component of RAAS and a receptor for SARS-CoV-2. It is expressed in many tissues with gastrointestinal (GI) tract ACE-2 levels far exceeding those in the respiratory tract. SARS-CoV-2 binding to its receptor results in a deficiency of ACE-2 activity in endocrine, intracrine, and local lung and GI tract ACE-2. The local ACE-2 has different organ-specific functions, including hypertension-independent activities; dysregulations of these functions may contribute to multiorgan COVID-19 pathology, its severity, long-term effects, and mortality. We review supporting evidence from this standpoint. Notably, COVID-19 comorbidities involving hypertension, obesity, heart disease, kidney disease, and diabetes are associated with gastrointestinal problems and display ACE-2 deficits. While RAAS inhibitors target both endocrine and intracrine ACE-2 activity, the deficit of the local ACE-2 activity in the lungs and more so in the gut have not been targeted. Consequently, the therapeutic approach to COVID-19 should be carefully reconsidered. Ongoing clinical trials testing oral probiotic bound ACE-2 delivery are promising.Keywords
This publication has 110 references indexed in Scilit:
- The Role of Tissue Renin-Angiotensin-Aldosterone System in the Development of Endothelial Dysfunction and Arterial StiffnessFrontiers in Endocrinology, 2013
- Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and DiseaseInternational Journal of Peptides, 2012
- The renin–angiotensin system and the gastrointestinal mucosaActa Physiologica, 2010
- Therapeutic Implications of the Vasoprotective Axis of the Renin-Angiotensin System in Cardiovascular DiseasesHypertension, 2010
- Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartanAmerican Journal of Physiology-Renal Physiology, 2009
- Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart FailureJACC, 2008
- Angiotensin-converting enzyme 2 in lung diseasesCurrent Opinion in Pharmacology, 2006
- Angiotensin-Converting Enzyme 2 (ACE2) and ACE Activities Display Tissue-Specific Sensitivity to Undernutrition-Programmed Hypertension in the Adult RatHypertension, 2005
- Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II ReceptorsHypertension, 2004
- Increased ACE 2 and Decreased ACE Protein in Renal Tubules From Diabetic MiceHypertension, 2004